Cannara Biotech Valuation
| LOVE Stock | CAD 0.80 0.12 17.65% |
Today, the firm appears to be overvalued. Cannara Biotech shows a prevailing Real Value of C$0.62 per share. The current price of the firm is C$0.8. Our model approximates the value of Cannara Biotech from analyzing the firm fundamentals such as Current Valuation of 113.72 M, return on equity of 0.0678, and Profit Margin of 0.07 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Cannara Biotech's valuation include:
Price Book 0.8188 | Enterprise Value 113.7 M | Enterprise Value Ebitda 7.4993 | Price Sales 0.9391 | Trailing PE 11.4286 |
Overvalued
Today
Please note that Cannara Biotech's price fluctuation is out of control at this time. Calculation of the real value of Cannara Biotech is based on 3 months time horizon. Increasing Cannara Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Cannara stock is determined by what a typical buyer is willing to pay for full or partial control of Cannara Biotech. Since Cannara Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Cannara Stock. However, Cannara Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.8 | Real 0.62 | Hype 0.75 |
The intrinsic value of Cannara Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Cannara Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Cannara Biotech helps investors to forecast how Cannara stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Cannara Biotech more accurately as focusing exclusively on Cannara Biotech's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Cannara Biotech's intrinsic value based on its ongoing forecasts of Cannara Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Cannara Biotech's closest peers.
Cannara Biotech Cash |
|
Cannara Valuation Trend
Analysing the historical paterns of Cannara Biotech's enterprise value and its market capitalization is a good way to estimate and gauge the value of Cannara Biotech over time and is usually enough for investors to make rational market timing decisions.
Cannara Biotech Total Value Analysis
Cannara Biotech is now anticipated to have takeover price of 113.72 M with market capitalization of 72.02 M, debt of 5.97 M, and cash on hands of 5.56 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Cannara Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
113.72 M | 72.02 M | 5.97 M | 5.56 M |
Cannara Biotech Investor Information
About 49.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.82. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Cannara Biotech had not issued any dividends in recent years. The entity had 1:10 split on the 13th of February 2023. Cannara Biotech is performing exceptionally good at this time. It has a great probability to report excellent financial results in January.Cannara Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cannara Biotech has an asset utilization ratio of 40.46 percent. This indicates that the Company is making C$0.4 for each dollar of assets. An increasing asset utilization means that Cannara Biotech is more efficient with each dollar of assets it utilizes for everyday operations.Cannara Biotech Ownership Allocation
Cannara Biotech holds a total of 90.02 Million outstanding shares. Cannara Biotech retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Cannara Biotech Profitability Analysis
The company reported the revenue of 57.26 M. Net Income was 6.95 M with profit before overhead, payroll, taxes, and interest of 17.33 M.About Cannara Biotech Valuation
Our relative valuation model uses a comparative analysis of Cannara Biotech. We calculate exposure to Cannara Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Cannara Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 31.3 M | 32.9 M | |
| Pretax Profit Margin | 0.05 | 0.06 | |
| Operating Profit Margin | 0.12 | 0.13 | |
| Net Profit Margin | 0.08 | 0.08 | |
| Gross Profit Margin | 0.36 | 0.56 |
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.